The Diabetes Care Devices Market is segmented by Management Devices (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors), Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The Industry Report Offers Values (USD Billion) for the Above Segments.

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

The Report Covers Germany Diabetes Management Companies and the Market is Segmented Into Monitoring Devices (Self-Monitoring Blood Glucose and Continuous Glucose Monitoring) and Management Devices (Insulin Pumps, Insulin Disposable Pens, Insulin Syringes, Cartridges in Reusable Pens, and Jet Injectors). The Market Provides the Value (in USD) and Volume (in Units) for the Above Segments.

The diabetes care device market size is projected to grow from USD 39.82 billion in 2025 to USD 99.81 billion by 2035, representing a CAGR of 9.62% during the forecast period till 2035

In 2023, the diabetes care devices market generated over 26 billion U.S. dollars in global revenues. The market was forecast to increase year-on-year and reach over 52.3 billion U.S. dollars by 2029.

The Report Covers APAC Diabetes Care Devices Market Trends, Dynamics & Size and It is Segmented Into Management Devices (insulin Pumps (insulin Pump Devices, Insulin Pump Reservoirs, and Infusion Sets), Insulin Syringes, Insulin Cartridges in Reusable Pens, Disposable Insulin Pens, and Jet Injectors), and Monitoring Devices (self - Monitoring Blood Glucose (glucometer Devices, Blood Glucose Test Strips, and Lancets) and Continuous Glucose Monitoring (sensors and Durables)), by End-User (Hospital/Clinics, Home/Personal) and Geography (Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, and Rest of Asia - Pacific). the Market Provides the Value (in USD) and Volume (in Units) for the Above-Mentioned Segments.

The Canada Diabetes Care Devices Market is segmented into management devices (insulin pumps, insulin syringes, disposable insulin pens, insulin cartridges in reusable pens, and insulin jet injectors) and monitoring devices (self-monitoring blood glucose (glucometer devices, test strips, and lancets) and continuous glucose monitoring (sensors and receivers (receivers and transmitters))). The report offers the value (in USD million) and volume (in units million) for the above segments.

Asia-Pacific Diabetes Care Devices Market size was valued at USD 8.2 Billion in 2023 and is anticipated to reach USD 15.7 Billion by 2031, growing at a CAGR of 8.5% from 2024 to 2031.

Key Market Drivers:
Rising Incidence of Diabetes: The Asia-Pacific region has a high prevalence of diabetes, with more than 60% of the world’s diabetic population residing in this area. For instance, India and China alone account for approximately 90 million and 62 million diabetics, respectively, highlighting the urgent need for effective diabetes management solutions.

Growing Geriatric Population: The aging population in Asia-Pacific countries is contributing to an increase in diabetes cases. The World Health Organization projects that the number of older adults (aged 60 and above) will reach 1.3 billion by 2050, leading to a higher demand for diabetes care devices tailored for elderly patients.

The size of the Diabetes Care Devices Market in Mexico market was valued at USD 503 Million in 2023 and is projected to reach USD 755.33 Million by 2032, with an expected CAGR of 5.98% during the forecast period.Diabetes care devices are very important tools to aid diabetic patients to manage their disorder. They help monitor blood sugar levels, administer insulin and log food intake. Blood glucose meters measure the blood sugar; patients can then take corrective action with their dosages of insulin or change their dieting habits. Insulin pumps administer insulin continuously or at programmed intervals, thereby providing greater accuracy for blood sugar control. Continuous glucose monitors monitor blood sugar levels throughout the day, though they measure in real time, they reduce the number of finger pricks needed for carbohydrate quantities. More amazingly, people have monitoring devices that record carbohydrate intake and calculate how much insulin is needed. All this has greatly improved the quality of life for the people affected with diabetes as it is almost impossible for better disease management, prevention of complications, and improved overall well-being. Recent developments include: October 2022: Becton, Dickinson, and Company and Biocorp signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology. It is a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes., June 2022: Abbott announced that it's developing a new bio-wearable that will continuously monitor glucose and ketone levels in one sensor. The glucose-ketone sensor will be the same size as Abbott's FreeStyle Libre 3 sensor, the world's smallest and thinnest continuous glucose monitoring sensor. It will connect to Abbott's digital ecosystem, including personal and caregiver mobile apps and cloud-based data management software for remote monitoring by healthcare professionals.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Continuous glucose monitoring segment is expected to witness highest growth rate over the forecast period.

The Thailand Diabetes Care Devices Market is projected to grow from a value of USD 128.94 million in 2025 to USD 215.40 million by 2033, exhibiting a CAGR of 6.36% during the forecast period (2025-2033). The increasing prevalence of diabetes, growing awareness about diabetes management, and technological advancements in diabetes care devices are driving the market growth. The growth of the market is also supported by the rising demand for continuous glucose monitoring (CGM) devices, which provide real-time glucose monitoring and help patients better manage their blood sugar levels. Additionally, government initiatives and reimbursement policies aimed at improving diabetes care are expected to further boost the market growth. The market is segmented into monitoring devices (self-monitoring blood glucose devices and continuous blood glucose monitoring), management devices (insulin pumps, insulin syringes, insulin cartridges, and disposable pens), and consumables (test strips and lancets). Key players in the market include Roche, Dexcom, Ypsomed, Abbott, Eli Lilly, Sanofi, Medtronic, Tandem, Insulet, Lifescan (Johnson & Johnson), and Becton and Dickenson. The Thailand diabetes care devices market is expected to witness a significant growth in the forecast period. Growing prevalence of diabetes, increasing awareness about diabetes management, and technological advancements in diabetes care devices are driving the growth of the market. Recent developments include: October 2023: Phillips-Medisize and GlucoModicum collaborated on the creation of a novel CGM device known as the Talisman. This innovative device integrates magnetohydrodynamic technology, advanced algorithms, and biosensors. Additionally, it is designed to connect to a smartphone application for efficient data collection., April 2022: the Insulin Pen has been approved by the Thailand Food and Drug Administration (TFDA) through the cooperation between Gan & Lee Thai partner and Gan & Lee. The approved Insulin Pen can be used with the Gan & Lee 3mL cartridge insulin penfill. By adjusting the dose knob, patients are allowed to set 1-60 units (U) of insulin for administration. The minimum scale of the pen is accurate to 1 unit (U), which can meet the needs of diabetic patients for daily injections.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Management Devices Segment is Having Highest Share in current year.

The pet diabetes care devices market is capturing a valuation of US$ 2.3 billion in 2023 and is expected to reach US$ 4.3 billion by 2033. The market is registering a CAGR of 6.2% during the forecast period.

Scope of Report

Japan diabetes devices market size reached USD 1,936 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,487 Million by 2033, exhibiting a growth rate (CAGR) of 2.8% during 2025-2033. Significant innovations and technological advancements, focused on addressing the multifaceted demands of diabetic management, monitoring, and treatment are primarily driving the market growth.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on type and distribution channel.

[213+ Pages Report] The global Diabetes Management Market size is expected to grow from USD 18.23 billion in 2022 to USD 36.02 billion by 2030, at a CAGR of 8.87% from 2023-2030

Access the summary of the Diabetes Care Devices market report, featuring key insights, executive summary, market size, CAGR, growth rate, and future outlook.

This statistic depicts the market share of the global top diabetes care devices manufacturers in 2011. In that year, Medtronic from the United States had a 7.5 percent share in the total global market for diabetes care devices.

Top diabetes care devices manufacturers

Diabetes is one of the leading causes of death in the United States. In 2010, 20.8 people per 100,000 of the U.S. population died due to diabetes. In the United States, 239 billion U.S. dollars was expended in 2013 to treat diabetes. However, in China, a country with one of the largest number of diabetics in the world, only 38 billion U.S. dollars was spent on diabetes health care. The diabetes care market is expected to grow to almost 16 billion U.S. dollars in the United States by 2017.

In 2011, F.Hoffman-La Roche Ltd and LifeScan, Inc. together are considered a large part of the top diabetes care device manufacturers in the world at 15.2 percent and 14.2 percent of the global market share, respectively. Lifescan is part of the Johnson & Johnson Company and has developed glucose monitoring devices such as OneTouch Ultra for home and hospital use. About 61 percent of global diabetes care devices can be listed under the glucose monitoring device category and 24 percent under insulin delivery devices. Insulin pump therapy has vastly improved since the 1970s, with alarms for malfunction and wireless connection to meters and computers. This type of device is a widely used product for diabetics around the world.

The Diabetes Care Devices Market in Indonesia is projected to reach a value of $140.04 million by 2033, growing at a CAGR of 5.73% during the forecast period (2025-2033). The market is primarily driven by the increasing prevalence of diabetes and the need for effective management and monitoring of blood glucose levels. Key drivers include rising disposable income, improved healthcare infrastructure, and advancements in technology. The market is segmented into monitoring devices and management devices. Monitoring devices include self-monitoring blood glucose devices (glucometers, test strips, and lancets) and continuous blood glucose monitoring (sensors and durables). Management devices encompass insulin pumps (insulin pump device, insulin pump reservoir, and infusion set), insulin syringes, insulin cartridges, and disposable pens. Major players in the Indonesian diabetes care devices market include Roche, Dexcom, Ypsomed, Abbott, Eli Lilly, Sanofi, Medtronic, Tandem, Insulet, Lifescan (Johnson & Johnson), Becton and Dickenson, and Novo Nordisk. Recent developments include: October 2023: Phillips-Medisize and GlucoModicum will collaborate on the creation of a novel CGM device known as the Talisman. This innovative device integrates magnetohydrodynamic technology, advanced algorithms, and biosensors. Additionally, it is designed to connect to a smartphone application for efficient data collection., February 2022: Indonesia's Ministry of Health launched a sectoral e-Katalog for medical devices. Previously, e-Katalog was managed by LKPP, referred to as the national e-Katalog, for all products procured by government institutions street lighting to pacemakers. LKPP e-Katalog is now split into a national e-Katalog for items required nationally and sectoral e-Katalogs, specific to ministries such as the Ministry of Health.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Management Devices Hold Highest Market Share in Indonesia Diabetes Care Devices Market.

Europe Digital Diabetes Management Market is Segmented Into Monitoring Devices (self-Monitoring Blood Glucose Devices (glucometer Devices, Blood Glucose Test Strips, And Lancets), Continuous Glucose Monitoring Devices (sensors and Durables (receivers and Transmitters))), Management Devices (insulin Pumps (insulin Pump Device, Insulin Pump Reservoir, And Infusion Set), Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, And Jet Injectors), And Geography (France, Germany, Italy, Spain, United Kingdom, Russia, And Rest of Europe). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

According to Cognitive Market Research, the global glucose monitoring devices market was valued at USD XX in 2023 and it is expected to grow at a CAGR of XX% from 2024 to 2029.

The global software engineering market will grow significantly by XX% CAGR between 2024 to 2029.
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market.
The report includes an analysis of the regional as well as market trends, key players, application areas, and market growth strategies.
Detailed analysis of Market Drivers, Restraints and Opportunities
North America dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.
The report consists size of the market.

Market Dynamics of Glucose Monitoring Devices

Key Drivers

Improving device synchronized data and accuracy for monitoring the glucose level drives the glucose monitoring device market

One of the most important aspects of the monitoring device is the accuracy with which it measures glucose levels. Accurate glucose monitoring is critical for successful diabetes management because it directly influences treatment decisions and patient outcomes. Several companies have developed advanced versions of conventional blood glucose monitors that are portable and minimally invasive. Many next-generation solutions include connectivity features that allow patients' health data to be captured and shared with medical professionals upon request. Companies are doing continuous innovation on the product for giving exact data to the customers. For Instance, in June 2024 Roche Holding AG receives CE mark for its AI enabled continuous glucose monitoring solution offering critical predictions to people living with 1 and type 2 diabetes n flexible insulin therapy. (source https://www.stocktitan.net/news/RHHBY/roche-receives-ce-mark-for-its-ai-enabled-continuous-glucose-i6j95ac2d9ie.html) Modern devices can now provide reliable and consistent readings, lowering the risk of complications caused by incorrect glucose measurements. Exact readings give patients more control over their blood glucose levels, resulting in fewer episodes of hyperglycemia or hypoglycemia. The development of continuous glucose monitoring (CGM) systems marks a significant technological advancement. Furthermore, accurate glucose monitoring devices are critical for healthcare providers because they allow for precise monitoring and individualized treatment plans. This can lead to more efficient resource utilization and improved patient outcomes, thereby driving market growth. As technology advances, glucose monitoring devices' accuracy is expected to improve even more, solidifying their role in effective diabetes management and expanding their global adoption.

Rising number of diabetes patients will further boost the glucose monitoring devices market

The growing incidence of diabetes among populations in both developed and undeveloped countries is leading to a large patient pool worldwide requiring blood monitoring, leading to an increase in demand for these devices among the patient population. Several factors, including rapid urbanization and the rising shift toward a sedentary lifestyle, in emerging and developed countries are primarily responsible for the growing prevalence of diabetes. For Instance, according to International Diabetes Federation (IDF) in 2021, it was estimated that around 537 million adults had diabetes, and China, India, U.S.A., Brazil and Mexico accounted for an estimated 51.6% of the global diabetes population in 2021. (source https://diabetesatlas.org/#:~:text=Diabetes%20around%20the%20world%20in%202021%3A,%2D%20and%20middle%2Dincome%20countries) A significant increase has been observed in the number of patients suffering from type-1 or insulin-dependent type 2 diabetes, which has been instrumental in surging the uptake of glucose monitoring systems globally. Thus, the presence of a large diabetic population with insulin-dependent diabetes, new product introductions by market players, and favorable reimbursement are driving demand and adoption of glucose monitoring devices

Restraints

The high cost of devices hinders the market growth

The glucose monitoring device is expensive and can be painful. Diabetes care devices do not always produce accurate results. Many hospitals and health...

This statistic depicts the distribution of the global diabetes care devices market pipeline in 2012. In that year, almost one out of four diabetes care devices in the pipeline worldwide was an insulin delivery device.

The revenue in the 'Diabetes Care Devices' segment of the medical technology market in Africa was forecast to continuously increase between 2024 and 2029 by in total 810.9 million U.S. dollars (+79.85 percent). After the twelfth consecutive increasing year, the revenue is estimated to reach 1.8 billion U.S. dollars and therefore a new peak in 2029. Notably, the revenue of the 'Diabetes Care Devices' segment of the medical technology market was continuously increasing over the past years.Find further information concerning the revenue in the 'General & Plastic Surgery Devices' segment of the medical technology market in Indonesia and the revenue change in the 'Medical Devices' segment of the medical technology market in Indonesia. The Statista Market Insights cover a broad range of additional markets.